Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 Trial of OMTX705 With Carboplatin, Pemetrexed and Tislelizumab in Advanced Non-squamous NSCLC
2025-521989-95-00Phase 2Authorised
- Sponsor
- Oncomatryx
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of OMTX705 in Non-small cell lung cancer (NS-NSCLC) (3 arms), sponsored by Oncomatryx. Planned start Dec 2025; status: authorised.
02
Drugs
OMTX705
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2025-521989-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521989-95-00.